ArticleJournal of endocrinological investigation2026
Functional hyperprolactinemia and subclinical primary hypothyroidism: myth or reality in clinical practice?
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperprolactinemia is a frequent clinical condition with different etiologies. Although primary hypothyroidism is often considered a leading cause of mild hyperprolactinemia, the supporting evidence is limited and often based on small studies with single prolactin (PRL) measurement, especially in cases of subclinical hypothyroidism. This study aims to evaluate the prevalence of thyroid dysfunction in patients assessed for functional hyperprolactinemia. PATIENTS AND
methodsThis retrospective study included patients undergoing cannulated PRL sampling (three measurements) and thyroid function assessment between January 2013 and May 2024, at Padova University-Hospital. Patients were stratified by PRL elevation and TSH levels. PRL-secreting pituitary adenoma and medication-induced hyperprolactinemia were exclusion criteria.
resultsOf 292 patients with available data, 229 fulfilled the inclusion criteria. Hyperprolactinemia was confirmed in 89/229 patients (39%). Among these, 26% had increased TSH compared to 16% in the normoprolactinemic group (p=0.083). PRL levels from cannulated samples and their mean values were not significantly higher in patients with hypothyroidism. No significant correlation was observed between TSH and PRL levels (Spearman's rho=0.053; p=0.428). The absence of association between TSH and PRL levels was confirmed also in a subgroup analysis in women of reproductive age.
conclusionOur findings suggest that subclinical hypothyroidism is common in patients evaluated for hyperprolactinemia: mild TSH increase should not delay the diagnostic evaluation for hyperprolactinemia, due to the low likelihood of thyroid dysfunction as the cause of hyperPRL.
Indexed as
Identifiers
42606813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.